Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Detalles Bibliográficos
Autores principales: Martin, Tom, Richardson, Paul G., Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, van de Velde, Helgi, Suzuki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521209/
https://www.ncbi.nlm.nih.gov/pubmed/35734925
http://dx.doi.org/10.3324/haematol.2022.280660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521209/
https://www.ncbi.nlm.nih.gov/pubmed/35734925
http://dx.doi.org/10.3324/haematol.2022.280660

Ejemplares similares